Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | STS | P08842 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9938875 | 0.92 | HPGD (0.56) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL583783 | 0.88 | HPGD (0.52) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL4239798 | 0.88 | HPGD (0.57) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL21995317 | 0.88 | HPGD (0.43) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL22051329 | 0.87 | HPGD (0.58) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL31663047 | 0.85 | HPGD (0.52) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL22043078 | 0.85 | HPGD (0.49) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL6105130 | 0.84 | HPGD (0.60) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL16604392 | 0.84 | HPGD (0.60) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL20012124 | 0.84 | KMT2A (0.55) | HPGDRECQLPTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166157-B | Double-acting mode soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20220031704-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-02-03 | — | — | US | disclosed |
| EP-3887376-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | Topadur Pharma AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| CN-113166157-A | Novel double-acting mode soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020109354-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031704-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE9A, PDE5A, PDE2A | HPGD 496/4885RECQL 716/4885PTPN2 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.